Abu Dhabi Investment Authority in Eikon Therapeutics, Inc.
Completed. First disclosed February 18, 2026, in a Schedule 13G (source).
- Investor
- Abu Dhabi Investment Authority (United Arab Emirates)
- Target
- Eikon Therapeutics, Inc. (EDGAR CIK 1861123)
- Target country
- United States
- Sector
- Health and Life Sciences (SIC 2836)
- First disclosed
- February 18, 2026, Schedule 13G
- Amount
- Not stated
- Stake at first disclosure
- 5.2%
- Latest stated stake
- 2.1% (October 2, 2026)
Source Filings and Releases
| Date | Document | Stated stake | Link |
|---|---|---|---|
| February 18, 2026 | Schedule 13G | 5.2% | View |
| October 2, 2026 | Schedule 13G/A | 2.1% | View |
Cite: Middle East Forum, “Abu Dhabi Investment Authority in Eikon Therapeutics, Inc.,” Gulf Sovereign Holdings, accessed October 13, 2026, https://statemoney.meforum.org/deal/adia-eikon-therapeutics-inc-1861123/.
Gulf money also reaches U.S. universities and lobbyists: the Influence Tracker holds Section 117 gift and contract disclosures and FARA registrations, and the Campus Watch Map places that funding on specific campuses.